Abstract
Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2% sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3%) and in 3 patients with 18F-FDG (16.7%) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85% of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20% (14 of 72) and 18F-FDG PET/CT 28% (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.
| Original language | English |
|---|---|
| Pages (from-to) | 569-580 |
| Number of pages | 12 |
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 39 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2012 |
Fingerprint
Keywords
- Diagnosis
- Medullary thyroid carcinoma
- Neuroendocrine tumours
- PET/CT
- Positron emission tomography
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. / Treglia, Giorgio; Castaldi, Paola; Villani, Maria Felicia; Perotti, Germano; De Waure, Chiara; Filice, Angelina; Ambrosini, Valentina; Cremonini, Nadia; Santimaria, Monica; Versari, Annibale; Fanti, Stefano; Giordano, Alessandro; Rufini, Vittoria.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 39, No. 4, 04.2012, p. 569-580.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
AU - Treglia, Giorgio
AU - Castaldi, Paola
AU - Villani, Maria Felicia
AU - Perotti, Germano
AU - De Waure, Chiara
AU - Filice, Angelina
AU - Ambrosini, Valentina
AU - Cremonini, Nadia
AU - Santimaria, Monica
AU - Versari, Annibale
AU - Fanti, Stefano
AU - Giordano, Alessandro
AU - Rufini, Vittoria
PY - 2012/4
Y1 - 2012/4
N2 - Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2% sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3%) and in 3 patients with 18F-FDG (16.7%) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85% of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20% (14 of 72) and 18F-FDG PET/CT 28% (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.
AB - Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2% sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3%) and in 3 patients with 18F-FDG (16.7%) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85% of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20% (14 of 72) and 18F-FDG PET/CT 28% (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.
KW - Diagnosis
KW - Medullary thyroid carcinoma
KW - Neuroendocrine tumours
KW - PET/CT
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=84862526634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862526634&partnerID=8YFLogxK
U2 - 10.1007/s00259-011-2031-6
DO - 10.1007/s00259-011-2031-6
M3 - Article
C2 - 22223169
AN - SCOPUS:84862526634
VL - 39
SP - 569
EP - 580
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 4
ER -